Therapeutic efficacy of intra-tumor AvidinOX and low systemic dose biotinylated cetuximab, with and without cisplatin, in an orthotopic model of head and neck cancer

Eitemau Tebyg

• Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer
  gan: Vesci, Loredana, et al.
  Cyhoeddwyd: (2015)
• Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab
  gan: Santis, Rita De, et al.
  Cyhoeddwyd: (2014)
• AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies
  gan: Milazzo, Ferdinando Maria, et al.
  Cyhoeddwyd: (2017)
• Radionuclide Therapy of Unresectable Tumors with AvidinOX and (90)Y-biotinDOTA: Tongue Cancer Paradigm
  gan: Albertoni, Claudio, et al.
  Cyhoeddwyd: (2015)
• Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer
  gan: Argiris, Athanassios, et al.
  Cyhoeddwyd: (2010)